Literature DB >> 3891077

Regulation of leukocyte glass adherence and tube leukocyte adherence inhibition (LAI) reactivity by serum factors in dogs with progressing or spontaneously regressing canine transmissible venereal sarcoma (CTVS).

M W Harding, T J Yang.   

Abstract

We examined the regulation of leukocyte glass adherence and tube leukocyte adherence inhibition (LAI) reactivity by serum factors in dogs with regressing or progressing canine transmissible venereal sarcomas (CTVS). Both regressor and progressor peripheral blood leukocytes (PBL), draining and non-draining lymph node cells (LNC), and splenic leukocytes were significantly responsive to CTVS antigen extract in tube LAI. In contrast, a significant decrease in basal glass adherence of progressor PBL, draining and non-draining LNC, and splenic leukocytes was observed. Normal glass adherence was restored to progressor leukocytes by extensive washing with warm serum-free media, while significant tube LAI responsiveness to CTVS antigen extract was maintained. Preincubation of regressor PBL and LNC with progressor sera in two-stage tube LAI decreased the basal glass adherence of treated leukocytes. This effect of progressor sera was heat labile, a characteristic of CTVS antigen. Collectively, these findings suggest that progressor leukocytes and progressor sera treated regressor leukocytes were activated by interaction with serum CTVS antigen and thus behaved in tube LAI as stimulated cells, even in the absence of CTVS antigen. Regressor but not progressor sera were shown to contain anti-CTVS IgG with specific arming activity for normal dog PBL, but not LNC in two-stage tube LAI. The nonadherent response of peripheral blood neutrophils in two-stage tube LAI was proportional to the concentration of arming IgG, whereas no change was observed in glass adherence of PBL. The results of this study define the role of progressor and regressor serum factors in the mechanism of tube LAI and demonstrate a relationship between leukocyte glass adherence and the clinical course of CTVS. These findings show that tube LAI is a simple and reproducible measure of active factors in the immune response to a tumor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891077     DOI: 10.1007/bf00199222

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

1.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

2.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

3.  A human colon tumour antigen associated with beta 2-microglobulin and isolated from solid tumour, serum and urine, is unrelated to carcinoembryonic antigen.

Authors:  D M Thomson; D N Tataryn; J C Weatherhead; P Friedlander; J Rauch; R Schwartz; P Gold; J Shuster
Journal:  Eur J Cancer       Date:  1980-04       Impact factor: 9.162

4.  Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell.

Authors:  N Grosser; J H Marti; J W Proctor; D M Thomson
Journal:  Int J Cancer       Date:  1976-07-15       Impact factor: 7.396

5.  Requirement for autologous cancer extracts and lipoxygenation of arachidonic acid for human T-cell responses in leukocyte adherence inhibition and transmembrane potential change assays.

Authors:  G Shenouda; D M Thomson; J K MacFarlane
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

6.  Blocking of the response by human T-lymphocytes to extracts of autologous cancer by monoclonal antibody to Class-I major histocompatibility complex gene products in the leukocyte adherence inhibition assay.

Authors:  G Shenouda; D M Thomson
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

7.  Leukocyte adherence inhibition: tumor specificity of cellular and serum-blocking reactions in human melanoma, breast cancer, and colorectal cancer.

Authors:  W J Halliday; T A Koppi; J M Khan; N C Davis
Journal:  J Natl Cancer Inst       Date:  1980-08       Impact factor: 13.506

8.  Isolation and characterization of canine venereal tumor-associated inhibitory and blocking factors.

Authors:  W E Beschorner; A D Hess; S T Nerenberg; R B Epstein
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

9.  Identification and physicochemical characterization of a tumor-associated antigen from canine transmissible venereal sarcoma.

Authors:  T J Palker; T J Yang
Journal:  J Natl Cancer Inst       Date:  1981-04       Impact factor: 13.506

10.  Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition.

Authors:  J H Marti; D M Thomson
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

View more
  2 in total

1.  Tumor size, leukocyte adherence inhibition and serum levels of tumor antigen in dogs with the canine transmissible venereal sarcoma.

Authors:  T J Yang; T J Palker; M W Harding
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma.

Authors:  T J Yang; J P Chandler; S Dunne-Anway
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.